Skip to main content
. 2024 Feb 6;30(3):762–771. doi: 10.1038/s41591-024-02805-1

Extended Data Table 4.

Detection of Anti-Drug Antibodies (ADAs) in serum over time

graphic file with name 41591_2024_2805_Tab4_ESM.jpg

The presence or absence of ADAs, quantified as positive or negative, at the indicated time points during the OMO-103 Phase I clinical trial is shown. Patient 102-001 ID changed to 102-401 when it was escalated to the next dose level. CRC: colorectal cancer; PDAC: pancreatic ductal adenocarcinoma; SCLC: Small Cell Lung Cancer; TNBC: Triple-Negative Breast Cancer; NSCLC: non-small-cell lung cancer. *Escalated to next dose level; **C6D8; ***C4D15.